Gilead Sciences said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.
The pacts allow the companies – Jubilant Life Sciences, Cipla , Hetero Labs, Mylan NV and Ferozsons Laboratories – to make and sell the drug in 127 countries.
The countries consist of nearly all low-income and lower-middle income ones, as well as several that are upper-middle- and high-income, the drugmaker said. Afghanistan, India, North Korea, Pakistan and South Africa are among the countries.
The licensees will also set their own prices for the generic product they produce, Gilead said.
The licenses are royalty-free until the World Health Organization declares the end of the public health emergency regarding COVID-19, or until a product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, the company said.
Gilead’s antiviral drug remdesivir earlier this month received the U.S. Food and Drug Administration’s emergency use authorization to treat COVID-19 patients.
